{"disease":{"id":"b-cell-lymphoma-unclassifiable-with-features-intermediate-between-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma","name":"b cell lymphoma unclassifiable with features intermediate between diffuse large b cell lymphoma and classical hodgkin lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02950220","title":"Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Kami Maddocks","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}